Abstract 3944
Background
We initially ascertained the value of inflammatory indexes in predicting severe acute radiation pneumonitis (SARP). Furthermore, we firstly built a novel nomogram and risk classification system integrating clinicopathological, dosimetric and biological parameters to individually and precisely identify SARP in patients with esophageal cancer (EC) who received radiotherapy (RT).
Methods
All data were collected from 312 EC patients. Logistic regression was used to choose predictors of SARP and then build nomogram. The validation of nomogram was performed by area under the ROC curve (AUC), calibration curves and decision curve analyses (DCA). A risk classification system was generated by recursive partitioning analysis (RPA).
Results
The Subjective Global Assessment (SGA) score, pulmonary fibrosis score (PFS), planning target volume/total lungs volume (PTV/LV), mean lung dose (MLD) and systemic immuneinflammation index (SII) were independent predictors of SARP and finally incorporated into the nomogram. The AUC of nomogram for SARP prediction was 0.852, which was much higher than any other factor (range, 0.604-0.712). Calibration curves indicated favorable consistency between the nomogram prediction and the actual outcomes. DCA exhibited satisfactory clinical utility. A risk classification system was built to perfectly divide patients into three risk groups which were low-risk group (7.1%, score 0–158), intermediate-risk group (38%, score 159–280), and high-risk group (71.4%, score>280).
Conclusions
SGA score, PFS, PTV/LV, MLD and SII were potential valuable markers in predicting SARP. The constructed nomogram and corresponding risk classification system with superior prediction ability for SARP could assist in patients counseling and guide treatment decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract